(Q28082065)

English

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Detlef Schuppan

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Natalie J Torok

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jonathan A Dranoff

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Scott L Friedman

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

1 reference

publication date

10 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

627-634

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

20 March 2017

Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

20 March 2017

Integrin-mediated activation of latent transforming growth factor beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

20 March 2017

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

20 March 2017

Mechanisms of fibrosis: therapeutic translation for fibrotic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

7 April 2017

The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

The changing burden of hepatitis C virus infection in the United States: model-based predictions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Origin of myofibroblasts in the fibrotic liver in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Integrins, myofibroblasts, and organ fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Liver fibrosis and repair: immune regulation of wound healing in a solid organ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Role of magnetic resonance elastography in compensated and decompensated liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Liver Injury and the Activation of the Hepatic Myofibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

The Gordian Knot of dysbiosis, obesity and NAFLD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Molecular MRI of collagen to diagnose and stage liver fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Evolving therapies for liver fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Mechanisms of pulmonary fibrosis: role of activated myofibroblasts and NADPH oxidase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Mechanisms of disease progression in NASH: new paradigms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Noninvasive methods to assess liver disease in patients with hepatitis B or C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Functional aspects on the pathophysiology of portal hypertension in cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Anti-fibrotic therapy: lost in translation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Quantitative histological-hemodynamic correlations in cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Scraping fibrosis: expressway to the core of fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Hepatic stellate cells require a stiff environment for myofibroblastic differentiation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Endothelin and hepatic wound healing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Animal models of non-alcoholic steatohepatitis: of mice and man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Portal fibroblasts: Underappreciated mediators of biliary fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Reversibility of liver fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Is Cirrhosis of the Liver Experimentally Produced by CC14 an Adequate Model of Human Cirrhosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

29 September 2017

Mesodermal mesenchymal cells give rise to myofibroblasts, but not epithelial cells, in mouse liver injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

2 June 2018

CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

2 June 2018

Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515973

2 June 2018

Exceeding the limits of liver histology markers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Liver stiffness diminishes with antiviral response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Synthesis and functional characterization of a fluorescent peptide probe for non invasive imaging of collagen in live tissues.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Elastin-based molecular MRI of liver fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

The serum proteome of nonalcoholic fatty liver disease: A multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

21 January 2018

Accelerated access to innovative medicines for patients in need

1 reference

https://pubmed.ncbi.nlm.nih.gov/25626988

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25626988

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/25626988

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Microparticles: Modulators and biomarkers of liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25626988

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/25626988

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.27720

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.27720

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28082065&oldid=1459086167"